Myositis clinical trials at UCSD

1 research study open to eligible people

Showing trials for

  • CTX112 in Adult Subjects With Refractory Autoimmune Disease

    open to eligible people ages 18-70

    This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).

    La Jolla, California and other locations

Our lead scientists for Myositis research studies include .

Last updated: